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Cardiovascular disease (CVD)-related chronic diseases are the leading cause of
death in societies with a large aged population such as Korea and Western
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Purpose: Elevated circulating oxidized low density lipoprotein (Ox-LDL) levels
are associated with increased risk of atherosclerosis, which may be due to high
plasma homocysteine (Hcy) and low intakes of antioxidants. We investigated the
contribution of dietary intakes of antioxidants to Hcy-induced LDL oxidation in
atherosclerotic patients (AP) and controls. Materials and Methods: Male AP (n =
101) who were confirmed by coronary angiography and 91 controls were evaluated
by blood biochemistry and dietary intakes. To determine whether homocysteine is
an independent risk factor for atherosclerosis, subjects were divided into three
groups; low- (≤ 6.9 uM/L), normal- (7 uM-12 uM/L) and high- (≥ 12.1 uM/L) Hcy.
Results: Plasm levels of homocysteine and LDL were higher, but plasma apo A-I
in HDL and folate were lower in the AP group. The odds ratio (OR) for the risk of
atherosclerosis was 3.002 [95% confidence interval (CI), 1.27-7.09] for patients in
the highest tertile with homocysteine ≥ 12.1 uM/L. AP having high homocysteine
levels had low intakes of vitamin A, β-carotene and vitamin C. By logistic
regression analysis, age, body mass index (BMI), plasma LDL, plasma folate, and
low intakes of vitamin A and β-carotene were found to be risk factors for
atherosclerosis in patients with high-Hcy, but dietary B vitamins including folate
were not. Conclusion: A high-Hcy level was a risk factor for atherosclerosis in
patients with high Ox-LDL levels. High intakes of antioxidants appeared to be a
protective factor for atherosclerosis, perhaps exerting a pro-oxidative effect on LDL
when combined with high levels of Hcy and LDL. However, more evidence for the
benefits of B vitamins as a homocysteine-lowering therapy is needed. 
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countries. Elevated levels of homocysteine (Hcy) above
12.1 µmol/L have been shown to double the risk of patho-
physiological conditions such as atherosclerosis, myocar-
dial infraction, cerebral or peripheral vascular diseases.1
Meta-analysis of 20 prospective studies indicated that the
odds ratios (OR) for the risk of ischemic heart disease and
stroke were 1.32 [95% confidence interval (CI), 1.19-1.45]
and 1.59 (95% CI, 1.29-1.96) for every 5 uM/L increase in
Hcy.2 Elevated Hcy may contribute to progressive atheros-
clerosis by several mechanisms, including arterial endo-
thelial function impairment, oxidative stress induction, and
the promotion of inflammation and thrombosis.1-4 
A recent randomized clinical trial, however, did not
support Hcy-lowering vitamin supplements to prevent
heart diseases.5 Since Hcy is a branch-point intermediate of
cystathionine and methionine metabolism, folate, B6, and
B12 are essential to the conversion of Hcy. It has been shown
that not only dietary B vitamin deficiency but also genetic
disorders, certain drugs, and renal impairment are related
to hyperhomocysteinemia.6,7 Folate and B12 supplements
decrease blood Hcy levels and carotid intima-media thick-
nening, but they do not inhibit LDL oxidation, a marker of
atherosclerosis.7,8 Attempts to delineate causative factors of
atherosclerosis have often investigated production of reac-
tive oxygen species (ROS) and reduction of availabilities
of endothelial nitric oxide (NO).9,10 Hcy is known to induce
oxidative stress and ROS or lipid peroxides (LPO) produc-
tion, and decrease NO availability.11,12 Hcy-induced ROS
has been shown to be related to impaired mitochondrial
NF-κB activation and NO bioavailability in endothelial
cells, cardiac myocytes, fibroblasts and leukocytes, how-
ever, they return to basal levels by antioxidants.9 Therefore,
Hcy affects the molecular structure or the activation of
control agents which participate in the oxidative mecha-
nism of atherosclerosis. 
The aim of the current study was to investigate whether
elevated Hcy levels are associated with oxidation of LDL,
and further explore the contribution of dietary intakes of B
vitamins or antioxidants to Hcy-induced LDL oxidation in
atherosclerosis. 
Subjects and samples
Healthy or atherosclerotic male subjects were recruited
from among in- and out-patients of Korea University
College of Medicine in Seoul, Korea, after approval from
Biomedical Human Subjects Review Committee. After
first screening (n = 340) with a health questionnaire (family
history, exercise), subjects were further evaluated with a
dietary survey and anthropometry [body mass index (BMI),
blood pressure (BP)]; biochemical tests were performed
for 192 final subjects. The 192 subjects were divided into
atherosclerosis patients (AP, n = 101) or control (n = 91)
groups after AP were diagnosed by coronary angiography
by a cardiologist. The coronary artery lesion was defined
where stricture levels of Lt. main, Lt. anterior descending
artery, left circumflex, or right coronary artery were over
50%. To determine whether Hcy is an independent risk
factor for CVD, subjects were assigned to one of three Hcy
levels, using the European Concerted Action Projects
(ECAP) cut-off value.13 Dietary surveys were performed
using the CANpro 3.0 software (developed by Korean
Nutrition Society). Survey results on dietary intakes and
biochemistry were statistically analyzed. None of the parti-
cipants were using vitamin and/or mineral supplements. 
Biochemical measurements 
Cholesterol and triglycerides (TG) were analyzed by enzy-
matic Kits (Sigma Co, St Louis, MO, USA).14,15 After HDL
and LDL were separated by density gradient ultracentri-
fugation, apo A-I in HDL and apo B-100 in LDL were
quantified by Western blotting analysis (antibodies; Santa
Cruz, CA, USA). In order to measure Ox-LDL, pure LDL
was high-speed centrifugated using KBr, at a density of
1.019-1.063 g/mL. During centrifugation, 0.1% EDTA
and 0.02% sodium azoid were  added. Phosphate-buffered
saline (PBS) was used for dialysis of centrifugated LDL.
SDS-polyacrylamine gel electrophoresis (PAGE) was used
to verify LDL purification.16 The purified LDL was dialyzed
for a day, and then LPO [malondialdehyde (MDA)] pro-
duction was analyzed. The thiobarbituric acid (TBA)
method (modified Packer and Smith method) was used to
obtain correct amount of lipid peroxide with the MDA
produced. By using 1,1,3,3-tetraethoxypropane as the stan-
dard reagent, comparisons were made between different
treatments according to thiobarbituric acid reactive sub-
stances (TBARS) values from different amounts of 1 mg
protein. Butylhydroxytoluen (BHT), sulfuric acid, and
Na2WO4 were mixed with LDL, and the mixture was cen-
trifugated. The liquid that rose was taken; NaOH and 1%
TBA were added and heated for 60 minutes at 100˚C. After
centrifugation at 3,000 rpm for 10 minutes, absorbance
was read.16-18 After the protein content of LDL was mea-
sured, units of LDL per mg protein were used to express
the amount. Total plasma Hcy (sum of free-, protein-
bound and mixed disulfide forms) in all samples was deter-
mined by the use of “Abbott IMX system Homocysteine
E/B3D390, 77-0650/R2” kit (ABBOTT Plasma Total Hcy
Diagnostic kit; Abbott, Abbott Park, IL, USA) in one run.19
By processing Hcy molecules (protein, residual thiol, or
sulfide combined) with DTT, a crystalline form of Hcy can
be obtained. By applying an S-adenosyl-L-homocysteine
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(SAH) hydrolase to the crystalline with cholesterol, the
amount of Hcy that combines with adenosine to form SAH
was measured. For determination of vitamin B12 and folate
in serum and plasma, vitamin B12/folate kit (Diagnostic
Products Corporation, Los Angeles, CA, USA) was used
according to the method of Soild Phase No Boil Dual-
couint.20: 200 µL of serum was mixed with sample buffer,
and the mixture was left for 30 minutes at room temper-
ature. The above samples were reacted with NaOH/KCN
at 37˚C, and vitamin B12/folate binder was added into each
tube. The supernatant after centrifugation at 2,000 g for 15
minutes was discarded. The radioactivity from 125I-folate
and 57Co-vit B12 in the pellet was measured by Gamma
counter Cobra II. For the amount of vitamin B12, pg/mL
was multiplied by 0.7378 to convert to pmol/L. For folate,
ng/mL was multiplied by 2.266 to convert to pmol/L. The
clinical reference value for blood vitatimin B12 is 200-950
pg/mL, and 3.0-17 ng/mL for blood folate.
Statistical analysis 
Using SAS statistical software (Carey, NC, USA), ANOVA
and independent t-test were performed. Statistical signi-
ficance was accepted at p-value < 0.05. Relationships among
variables were assessed by correlation analysis. Univariate
and multivariate logistic regression analyses were used to
obtain the crude and adjusted OR (AOR) and 95% CI. 
Demographics of subjects
Average age of the AP group was 56.2 years, while the
average age of the control group was 42.4 years. The two
groups exhibited no differences in blood pressure and BMI
(Table 1). Over 60% of the AP subjects exhibited other co-
morbidities also, whereas 73% of controls were disease-
free. The incidences of hypertension and diabetes were
35% and 16%, respectively, in the AP (data not shown).
Smoking and drinking rates were similar in both groups,
but the amount and length of the use were much higher in
the AP; 47.7% of total AP smoked more than 1 pack of
cigarettes/day (control: 32.2%) and 35.5% of the AP drank
2-4 times/week (control: 28.8%). The AP also had higher
coffee consumption rate (5 cups/day) than the control (data
RESULTS
Table 1. Mean Values (± SD) of General Characteristics, Blood Parameters and Daily Nutrient Intakes of 
Folate and Antioxidants Related to Atherogenic Risk Factors in AP and Control Groups
AP group (n = 101) Control (n = 91) p value 
Age (yrs) 56.2 ± 12.4 42.4 ± 8.8 0.002
BMI (kg/m2) 24.7 ± 3.1 23.9 ± 2.3 0.087
Blood Parameters
Systolic BP (mmHg) 131.5 ± 21.7 129.9 ± 11.4 0.560
Diastolic BP (mmHg) 81.2 ± 13.7 82.3 ± 9.23 0.554
HCY (uM/L) 12.98 ± 6.82 11.19 ± 4.54 0.032
T-C (mg/dL) 186.5 ± 39.0 179.6 ± 35.4 0.267
HDL-C (mg/dL) 40.3 ± 12.0 39.9 ± 22.3 0.877
LDL-C (mg/dL) 119.2 ± 36.6 108.3 ± 33.6 0.049
Ox-LDL* (uM/mg) 249.0 ± 112.0 225.7 ± 90.6 0.115
TG (mg/dL) 135.0 ± 80.9 156.9 ± 75.7 0.097
Apo A-1 (mg/dL) 118.6 ± 18.7 134.8 ± 19.1 0.000
Apo B-100 (mg/dL) 87.2 ± 19.8 92.3 ± 22.4 0.091
Vit B12 (pg/mL) 425.0 ± 144.0 448.0 ± 161.0 0.312
Folate (ng/mL) 6.6 ± 2.7 7.7 ± 4.0 0.025
Dietary Iintakes of Folate and Antioxidants�
Folate (µg) 277.4 ± 108.5 302.6 ± 108.8 0.130
Vit A (µg RE) 964.6 ± 571.2 815.9 ± 471.8 0.063
β-carotene (µg) 4790 ± 3174 4261 ± 2804 0.246
Vit C (mg) 93.9 ± 50.2 124.1 ± 63.9 0.001
Vit E (mg) 12.7 ± 7.6 13.8 ± 5.8 0.326
BMI, body mass index; Hcy, homocysteine; T-C, total cholesterol; LDL, low density lipoprotein; HDL, high density lipoprotein; TG, 
triacylglycerol; Vit, vitamin; BP, blood pressure.
*Oxidized LDL; malondialdehyde (uM) concentration per mg LDL protein.
�Adjusted by the calorie intake.
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not shown).
Blood lipid profiles, folate & B12 in AP or 
hyperhomocysteinemia 
In the AP, blood Hcy and LDL cholesterol levels were
higher and apo A-I in HDL and folate were lower, exhibit-
ing characteristic lipid spectrum of atherosclerosis (Table 1).
Plasma Hcy and LDL can be viewed as pro-arteriosclerosis
factors, and HDL’s apo A-I as an anti-arteriosclerosis
factor. However, no apparent differences in total choles-
terol (T-C), HDL, TG, and apo B-100 were observed bet-
ween AP and control. Blood Hcy and Ox-LDL were higher
in AP, suggesting that Hcy plays a role in LDL oxidation.
Blood folate levels were lower in AP, whereas vitamin B12
levels were similar. In order to verify the changes in lipid
profiles, resulting from the effects of vitamins and Ox-
LDL on Hcy concentrations, subjects were divided into 3
groups depending on Hcy levels: low-Hcy (≤ 6.9 uM/L),
normal (7 uM-12 uM/L) and high-Hcy (≥ 12.1 uM/L)
(Table 2). Ox-LDL levels were not different between AP
and control, but signifi-cantly higher in the normal and
high-Hcy groups than in the low-Hcy group (Table 2). The
positive association of LDL with Ox-LDL was stronger in
high-Hcy subjects than that in total subjects, normal or low
Hcy subjects (data not shown). The increased Ox-LDL in
the high-Hcy group can be explained as LDL oxidation
caused by the increase in blood Hcy. Blood folate levels
were significantly different (p < 0.05) among the 3 Hcy
groups, and it was negatively correlated with Hcy (Fig. 1).
There was no correlation bet-ween vitamin B12 and Hcy
even though blood folate and vitamin B12 were positively
correlated (data not shown). The blood lipid levels did not
change according to Hcy levels and were not correlated
with Hcy. 
Dietary intakes in AP or hyperhomocysteinemia 
The relative percentages of carbohydrate, protein and fat
intakes per total calories were similar in AP and controls,
Table 2. Mean Values (± SD) of Blood Metabolic Variables and Daily Nutrient Intakes of Folate and Antioxi- 
dants According to the Classification of Plasma Hcy Levels
Low-Hcy Normal-Hcy High-Hcy
(≤ 6.9 µM/L) (7 - 12 µM/L) (≥ 12.1 µM/L) p value 
(n = 9) (n = 112) (n = 53)
Age (yrs) 54.8 ± 17.1 47.9 ± 11.9 51.8 ± 13.3 0.077
BMI (kg/m2) 24.9 ± 3.7 24.4 ± 2.6 23.9 ± 2.8 0.430
Blood pressure and blood variables
Systolic (mmHg) 128.2 ± 28.3 132.4 ± 16.8 127.6 ± 16.3 0.229
Diastolic (mmHg) 82.1 ± 14.4 82.1 ± 10.9 80.8 ± 13.0 0.807
HCY (uM/L) 6.5 ± 0.3a) 9.5 ± 1.3b) 18.1 ± 7.2c) 0.000
T-C (mg/dL) 199.6 ± 29.9 183.1 ± 38.7 182.3 ± 36.3 0.566
HDL-C (mg/dL) 37.6 ± 20.7 38.5 ± 13.3 43.5 ± 22.4 0.251
LDL-C (mg/dL) 131.1 ± 28.4 144.8 ± 35.7 111.9 ± 36.4 0.461
Ox-LDL* (uM/mg) 161.6 ± 76.0a) 237.6 ± 108.2b) 255.3 ± 95.7b) 0.005
TG (mg/dL) 154.2 ± 66.7 148.8 ± 49.4 134.6 ± 79.9 0.577
Apo A-1 (mg/dL) 124.2 ± 24.7 128.1 ± 20.9 123.0 ± 18.7 0.280
Apo B-100 (mg/dL) 93.7 ± 17.2 90.9 ± 21.9 86.1 ± 19.8 0.318
Vit B12 (pg/mL) 438.2 ± 139.6 452.4 ± 159.3 402.2 ± 136.5 0.121
Folate (ng/mL) 6.9 ± 3.7b) 7.6 ± 3.7c) 6.1 ± 2.4a) 0.023
Dietary intakes of folate and antioxidants�
Folate (µg) 351.0 ± 180.1 289.4 ± 107.6 282.6 ± 95.9 0.217
Vit A (µg RE) 1370 ± 1219b) 880 ± 484a) 820 ± 381a) 0.013
β-carotene (µg) 7166 ± 7436b) 4483 ± 2626a) 4137 ± 2267a) 0.018
Vit C (mg) 170.9 ± 66.4b) 105.0 ± 56.1a) 108.9 ± 60.6a) 0.006
Vit E (mg) 16.2 ± 8.3 13.4 ± 7.0 12.7 ± 5.9 0.329
BMI, body mass index; Hcy, homocysteine; T-C, total cholesterol; LDL, low density lipoprotein; HDL, high density lipoprotein; TG, 
triacylglycerol; Vit, vitamin.
a), b), c) Values within the classification of plasma HCY levels with different superscripts are significant at p < 0.05.
*Oxidized LDL; malondialdehyde (uM) concentration per mg LDL protein.
�Adjusted by the calorie intake.
even though AP had lower energy intakes (data not shown),
suggesting that AP might have attempted to lose weight,
since they had slightly, but not significantly, higher BMIs.
Dietary intakes of other B vitamins were not different
between the two groups, except vitamin B1 and B2 which
were lower in AP. Vitamin B12 intake could not be evaluated
because of insufficient data. There were no differences in
any dietary intakes except vitamin A, β-carotene and
vitamin C among the three Hcy groups (Table 2). Hcy was
not affected by dietary folate intakes in this study, and the
pattern of correlation between dietary folate and Hcy or
plasma folate were not obvious (Fig. 1). Therefore, low
dietary folate in AP might have not induced hyperhomo-
cysteinemia in this study. However, dietary intakes of
vitamin A, and its precursor, and vitamin C were signifi-
cantly lower with increasing Hcy. The negative correla-
tions between dietary vitamin A (r2 = - 0.226) or β-carotene
(r2 = - 0.233) antioxidants and Ox-LDL were also signi-
ficant in AP (p < 0.001) compared to no correlations in
controls (data not shown).
Risk factors for atherosclerosis according to Hcy levels
Using the ECAP cut-off value (≥ 12.1 uM/L), 26.6% of the
total Korean male subjects had hyperhomocysteinemia,
and 69.3% and 4.2% had normal and low-Hcy levels,
respectively. The frequency of atherosclerosis was sub-
stantially increased if the blood Hcy was higher than ≥ 12.1
uM/L (OR, 2.887; 95% CI, 1.51-5.53) and this status was
stronger after adjusting for age and BMI (AOR, 3.002;
95% CI, 1.27-7.09)(data not shown). To identify links bet-
ween risk factors for atherosclerosis and high blood Hcy
levels, all anthropometric and biochemistry variables and
daily nutrient intakes were subjected to logistic regression
analysis (Table 3). The AOR for atherosclerosis was 4.420
(95% CI, 1.542-12.663) with high blood Hcy and LDL
levels compared to when LDL was not included as a factor
Hongseog Seo, et al.
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Table 3. Logistic Regression Analysis of Independent Risk Factors for Korean Male Atherosclerosis with High Hcy Levels
Variables
Adjusted OR (95% CI)�
I II III IV
Blood HCY§ 3.002 (1.269 - 7.088)� 3.037 (1.113 - 8.292)* 4.420 (1.542 - 12.663)� 4.206 (1.457 - 12.142)�
Dietary Folate 1.001 (0.997 - 1.005)
Plasma Folate 0.797 (0.670 - 0.949)�
LDL 1.014 (1.000 - 1.028) * 1.013 (1.000 - 1.028)*
Dietary β-carotene 
1.000 (1.000 - 1.000)
(or vit A)
‖
Hcy, homocysteine; LDL, lowdency lipoprotein; BMI, body mass index.
*p < 0.05.
�p < 0.01.
�Risk factors for atherosclerosis were analyzed by logistic regression analysis. All variables of odds ratios for atherosclerosis were adjusted by age and BMI. 
§High blood Hcy (serum HCY levels ≥ 12.1 uM/dL). 
‖Same when vit A variable was included.
Fig. 1. Correlation between plasma folate or dietary folate and Hcy
concentration in adult Korean men. Plasma folate levels were significantly and
negatively correlated with Hcy concentration, but not with dietary folate.
(Model I & II). When dietary folate and plasma were
added, the AOR of high-Hcy for atherosclerosis was not
changed. After dietary vitamin A and β-carotene were
included as antioxidants, the AOR of high-Hcy for ather-
osclerosis was reduced to 4.206 (95% CI, 1.457-12.142).
We demonstrated that the most important risk factor for
atherosclerosis was LDL and the least important risk factor
was plasma folate in hyperhomocysteinemia. When par-
ticipants were divided into tertiles of mean Hcy and LDL
concentrations, 20.7% of subjects in the 3rd tertile of Ox-
LDL (276.13-745 uM/mg LDL) came under two combined
categories with the highest Hcy (11.89-50 uM/L) and LDL
levels (124.81-244 mg/dL) (Fig. 2). The probability of sub-
jects having the highest Ox-LDL while also having low
Hcy and low LDL levels was only 3.4%. We found that the
greatest progression of atherosclerosis was observed with
the highest Ox-LDL simultaneously with both the highest
Hcy and LDL concentrations. This means that a high cir-
culating Hcy level was a risk factor for atherosclerosis only
when the subject had also elevated LDL levels 
In this study, AP exhibited multiple complications causing
co-morbidities of metabolic syndrome such as hyper-
tension and NIDDM, which were similar to the distri-
bution of complications seen in Korean hyperlipopro-
teinemia.21 The ECAP study found that elevated Hcy was
an independent risk factor for Hcy and CVD, causing
multiple effects on the risks of smoking, hypertension, and
hypercholesterolemia.13 It has been reported that 85.2% of
Korean AP smoke 20 cigarettes/day or more, and 85.4% of
AP smoked more than one pack of cigarettes/day for the
last month.1 Since elevated Hcy strongly correlates with
smoking and low blood folate levels were found in the
PRIME case-control study, Hcy levels might be a secon-
dary risk factor to low blood folate and smoking.22 Elevated
Hcy may also be involved in hypertension because it is
associated with impaired endothelial function due to the
generation of oxidative stress, VCAM-1 and reduction of
NO bioavailability.23,24 High dietary intake of sodium is
also a cause of hypertension. Since Koreans customarily
consume large amounts of traditional salty fermented
foods such as kimchi or soybean paste, sodium intake is
almost 3 times higher than the DRI established by WHO
(2 g/day). In American adults, blood Hcy levels are 5-15
µmol/L, and Hcy concentration of the control (healthy)
group is around 7-12 µM/L.25 In Jacques’ study,26 male
coronary artery disease patients (age, 43-57 years) had Hcy
concentrations of 13.66 uM/L while the control had 10.93
uM/L concentration. If the total blood Hcy is low, the death
rate of CVD is low. Every 5 µM/L increase in the Hcy con-
centration increases the risk of CVD by 50%, and TC levels
by 20 mg/dL.1,2,25,26 While doubts were raised concerning the
cause-effect relationship between the Hcy and CVD, we
found that Hcy is definitely higher in AP than in controls. 
The mechanisms possibly responsible for causing
endothelial dysfunction include changes in LDL, and Ox-
LDL, since higher LDL, which is associated with oxida-
tion of LDL was observed in the AP. We also found that
elevated Hcy makes the correlation between LDL and Ox-
LDL much stronger. In Mansoor’s research, Hcy levels
and Ox-LDL were higher in subjects with CAD than in
control. The oxidation of LDL is increased by the com-
bination of thiolactone and apo B’s free lysyl epsilon
amino residue.10,27,28 When LDL is reacted with Hcy-
thiolactone in methionine, which is an explicit initiator of
arteriosclerosis, LDL-binding thiol is increased by 250 nM
per mg of LDL protein.29 The free amino- or thiol-adducted
LDL causes aggregation, and increases LDL uptake in
macrophages and atheroma production by lipids.30 In
Marek’s research, LDL oxidation in the aortic cell walls
was 40% higher in hyper-homocysteinemia (≥ 14.0 µM/L)
compared to control.31 Another mechanism by which Hcy
may cause LDL oxidation is a possible deformation of
LDL through Hcy autoxidation, which causes the oxida-
tion of side chains of LDL such as fatty acids or apo B-
100.7 Both Hcy and Ox-LDL could participate in throm-
bosis by increasing VCAM-1 and ICAM-1, caused by
endothelial cell activation due to fibrinogen-platelet GPIIb-
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DISCUSSION
Fig. 2. The participants (n = 192) were divided into tertiles of mean Hcy and LDL
levels. The greatest progression of coronary atherosclerosis was observed in
subjects with Ox-LDL 3rd tertile corresponding to highest Hcy and LDL levels.
Left, The frequencies (%) in subjects having highest Ox-LDL according to tertiles
of Hcy and LDL concentrations. Hcy (uM/L): small tertile, < 9.3; medium tertile,
9.31 to 11.89; large tertile, > 11.90. LDL levels (mg/dL): low tertile, < 96.9; medium
tertile, 97 to 124.8; high tertile, > 124.81. Ox-LDL (uM/mg): low tertile, < 183.58;
medium tertile, 183.59 to 276.12; high tertile, > 276.13. LDL, low density lipoprotein;
Ox-LDL, oxidized LDL; Hcy, homocysteine.
lIIa formation. Ox-LDL affects both initial and progressive
stages of arteriosclerosis.11,12,23,32 On the other hand, circulat-
ing Hcy reduced NO-induced detoxification, vasodilation,
and endothelial function.10 NO participates in a metabolic
pathway (S-nitroso-HCY) that is able to protect against
Hcy-induced endothelial oxidative damage. 
Since Hcy is a branch-point intermediate of cystathionine
and methionine metabolism, the deficiency of B vitamins
(folate, vitamin B6 and B12) might cause hyperhomocystei-
nemia.4,33 In animal and clinical tests, vitamin B12 and folate
deficiency is related to increased blood Hcy levels, but the
correlation between Hcy and B vitamins is not clear.34,35 In
the Hcy- Lowering Trial’s Collaboration Research, an
additional 7% supplement of vitamin B12 reduced fasting
Hcy levels and decreased hypercysteinemia by 25%,
however, vitamin B6 had no effect on Hcy levels.5,25 In Ver-
meulen’s  research, where AP was given 5 mg of folate
and 250 mg of vitamin B6, the Hcy level decreased from
14.7 µM/L to 7.4 µM/L, showing a higher reduction rate
than in the placebo group (12.0 µM/L).36 Supplemention of
folate (2.5 mg), vitamin B6 (25 mg), and B12 (500 µg) for
one year reduced Hcy from 10.5 to 6.56 µM/L and carotid
intima-media thickness by 5.3%.8,37 However, Young and
Woodside reported that supplementary folate and vitamin
B12 lower blood Hcy levels, but they cannot stop LDL
oxidation.7 Vitamins B12 or B6 and the C677T NTHFR poly-
morphism have not been associated with carotid intima-
media thickness.8 Food-based feeding trials have shown a
reduction in blood Hcy in subjects who consume fortified
cereals or whole grains in combination with fruits, vege-
tables and low fat dairy products.38,39 However, more evi-
dence is needed for the association of vitamin B12 and Hcy
levels with the pro-oxidative mechanism of LDL and the
dietary benefits of Hcy-lowering therapy for atheros-
clerosis. The effects of antioxidants on decreasing the
oxidation of LDL may be an important observation when
blood LDL and Hcy levels are increased. Because low
intakes of vitamin A, β-carotene and vitamin C are asso-
ciated with Hcy levels, even though the biochemical data
did not support that the Hcy-induced oxidative damage is
protected by antioxidants. Both hydro- and lipid-soluble
antioxidants have been shown to be depleted in oxidative
endothelial damage.10,40 Our findings confirmed a role of
antioxidant compounds, particularly β-carotene, against
the oxidative damage promoted by Hcy and elevated LDL
levels. Nevertheless, it needs to be further evaluated in
conjunction with markers of oxidative damage. 
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